Identification of Fragile X Syndrome Specific Molecular Markers in Human Fibroblasts: A Useful Model to Test the Efficacy of Therapeutic Drugs
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the most frequent cause of inherited intellectual disability and autism. It is caused by the absence of the fragile X mental retardation 1 (FMR1) gene product, fragile X mental retardation protein (FMRP), an RNA-binding protein involved in the regulation of translation of a subset of brain mRNAs. In Fmr1 knockout mice, the absence of FMRP results in elevated protein synthesis in the brain as well as increased signaling of many translational regulators. Whether protein synthesis is also dysregulated in FXS patients is not firmly established. Here, we demonstrate that fibroblasts from FXS patients have significantly elevated rates of basal protein synthesis along with increased levels of phosphorylated mechanistic target of rapamycin (p-mTOR), phosphorylated extracellular signal regulated kinase 1/2, and phosphorylated p70 ribosomal S6 kinase 1 (p-S6K1). The treatment with small molecules that inhibit S6K1 and a known FMRP target, phosphoinositide 3-kinase (PI3K) catalytic subunit p110β, lowered the rates of protein synthesis in both control and patient fibroblasts. Our data thus demonstrate that fibroblasts from FXS patients may be a useful in vitro model to test the efficacy and toxicity of potential therapeutics prior to clinical trials, as well as for drug screening and designing personalized treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 1×
“It is localized in somatodendritic compartments of neurons where it mainly represses the translation of target mRNAs by ribosomal stalling [Darnell et al., 2011].”
BackgroundFragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015 · cited 1×
“We then examined the levels of activated p70 ribosomal S6 kinase 1 (S6K1), which is a common downstream effector of mTORC1 and ERK1/2 and directly regulates molecules that are components of translation initiation and elongation machinery [Magnuson et al., 2012].”
BackgroundTranslational control of long-lasting synaptic plasticity and memory
Costa-Mattioli, M., Sossin, W. S., Klann, E., & Sonenberg, N. (2009) · Neuron · doi:10.1016/j.neuron.2008.10.055 · Cited by 944
Self-citationDNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
Dendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome
Irwin, S. A. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.1038 · Cited by 626
Dysregulation of mTOR signaling in fragile X syndrome
Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., & Zukin, R. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3696-09.2010 · Cited by 557
Self-citationMolecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective
Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528 · cited 1×
“FMRP is a negative regulator of translation and its loss leads to exaggerated protein synthesis rates in the brains of Fmr1 KO mice resulting in synaptic dysfunction and altered spine morphology [Irwin et al., 2000; Santoro et al., 2012].”
BackgroundThe translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491 · cited 1×
“The loss of FMRP is believed to cause dysregulated translation of its target mRNAs, many of which are critical for synaptic plasticity, maintaining neuronal function and regulatory control of protein synthesis [Darnell and Klann, 2013].”
BackgroundSelf-citationChronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Muddashetty, R. S., Kelić, S., Gross, C., Xu, M., & Bassell, G. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0937-07.2007 · Cited by 421
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome
Hinds, H. L., Ashley, C. T., Sutcliffe, J. S., Nelson, D. L., Warren, S. T., Housman, D. E., & Schalling, M. (1993) · Nature Genetics · doi:10.1038/ng0193-36 · Cited by 396 · cited 1×
“FMRP is primarily an RNA-binding protein that is ubiquitously expressed during early embryonic development and highly expressed in postnatal brain and gonads [Hinds et al., 1993; Hergersberg et al., 1995].”
BackgroundOsterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384 · cited 6×
“Here, we show in primary fibroblasts derived from nine controls and eight FXS patients that basal protein synthesis rates as measured by the incorporation of [(3)H]leucine, while variable, are indeed significantly elevated in primary FXS fibroblasts, suggesting that human fibroblasts recapitulate the dysregulated prot…”
BackgroundMethodInfluentialBhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., & Klann, E. (2012) · Neuron · doi:10.1016/j.neuron.2012.07.022 · Cited by 316
Self-citationQin, M., Kang, J., Burlin, T. V., Jiang, C., & Smith, C. B. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0093-05.2005 · Cited by 263
Self-citationHenderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004218 · Cited by 249 · cited 2×
“…manipulation and pharmacological treatment of Fmr1 KO mice with drugs that normalize rates of protein synthesis have been shown to correct some molecular and behavioral phenotypes [Bhattacharya et al., 2012; Henderson et al., 2012; Liu et al., 2012; Michalon et al., 2012; Osterweil et al., 2013].”
BackgroundTargeting the endocannabinoid system in the treatment of fragile X syndrome
Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C., Pastor, A., Mato, S., Pérez-Samartín, A., Matute, C., de la Torre, R., Dierssen, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3127 · Cited by 241
Osterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230 · cited 4×
“…targeted using pharmacogenetic approaches to rescue a plethora of phenotypes expressed in FXS model mice and flies [McBride et al., 2005; Dolen and Bear, 2008; Gross et al., 2010; Westmark et al., 2011; Bhattacharya et al., 2012; Franklin et al., 2013; Osterweil et al., 2013; Udagawa et al., 2013].”
BackgroundInfluentialAltered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., Whelan, A. M., Zukin, R. S., Klann, E., & Tassone, F. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00768.x · Cited by 198
Self-citationFragile X: Leading the Way for Targeted Treatments in Autism
Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176
De Rubeis, S., & Bagni, C. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.09.013 · Cited by 126 · cited 1×
“FMRP is an extensively studied protein that is thought to be instrumental in mRNA packaging, transport, and activity-dependent translation regulation [Bassell and Warren, 2008; De Rubeis and Bagni, 2010].”
BackgroundReversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110 · cited 1×
“…targeted using pharmacogenetic approaches to rescue a plethora of phenotypes expressed in FXS model mice and flies [McBride et al., 2005; Dolen and Bear, 2008; Gross et al., 2010; Westmark et al., 2011; Bhattacharya et al., 2012; Franklin et al., 2013; Osterweil et al., 2013; Udagawa et al., 2013].”
Background
Cited by
Dysregulation and restoration of translational homeostasis in fragile X syndrome
Richter, J. D., Bassell, G. J., & Klann, E. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4001 · Cited by 275
“G-rich G-rich sequences in the 3 ′ UTR of the mRNA of the important synapse component postsynaptic density protein 95 (PSD95; also known as DLG4) 51 occur within regions that are binding sites for miR-125a and FMRP 41,52 .”
BackgroundSelf-citationLozano, R., Rosero, C. A., & Hagerman, R. J. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01022 · Cited by 186
Autism and the synapse: emerging mechanisms and mechanism-based therapies
Ebrahimi-Fakhari, D., & Sahin, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000186 · Cited by 167
“Fmr1-null mice [37,38] and fibroblasts derived from FXS patients [39] show activation of mTOR signaling with higher levels of mTOR kinase activity and increased phosphorylation of downstream targets S6 kinase and 4E-BP.”
BackgroundNguyen, L. S., Lepleux, M., Makhlouf, M., Martin, C., Fregeac, J., Siquier-Pernet, K., Philippe, A., Feron, F., Gepner, B., Rougeulle, C., et al. (2016) · Molecular Autism · doi:10.1186/s13229-015-0064-6 · Cited by 158
“Indeed, primary human fibroblasts are readily accessible untransformed cells that have been previously used as model for neuropsychiatric disorder studies [24, 25], and PBMCs are suitable for screening of large cohorts.”
BackgroundTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
“While mouse studies with lithium and a specific GSK3β antagonist already show promising effects on behavior and cognition in FXS mice [122, 123, 134, 155], so far, p110β-selective inhibitors have only been validated in vitro in mice and in vivo in patient-derived cell lines [64, 66].”
Background
Metadata
- Authors
- Kumari, D., Bhattacharya, A., Nadel, J., Moulton, K., Zeak, N. M., Glicksman, A., Dobkin, C., Brick, D. J., Schwartz, P. H., Smith, C. B., Klann, E., & Usdin, K.
- Venue
- Human Mutation
- Publisher
- Wiley
- Published
- 2014-11-24
- Volume
- 35
- Issue
- 12
- Pages
- 1485-1494
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2046162455
- Cited by
- 60
- References
- 22
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.